Adenocarcinoma of the Gastroesophageal Junction

About
Mappings

OncoTree: Adenocarcinoma of the Gastroesophageal Junction (oncotree:GEJ)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine FDA
Sensitivity (+) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab FDA
Sensitivity (+) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab FDA
Sensitivity (+) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab FDA
Sensitivity (+) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Pembrolizumab FDA
Sensitivity (+) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan FDA
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab FDA
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab FDA
Sensitivity (+) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab FDA
Sensitivity (+) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan HC
Sensitivity (+) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab HC
Sensitivity (+) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab HC
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab HC